CVS Caremark Expands Coverage for Lilly's Zepbound and Foundayo, Boosting Access for 90M Lives
Summary
CVS Caremark will significantly expand coverage for Eli Lilly's key obesity drugs, Zepbound and Foundayo, adding them to preferred commercial formularies and covering approximately 90 million lives. Zepbound coverage begins October 1, and Foundayo on June 1. This move, coupled with insured patients potentially paying as little as $25/month for these GLP-1 drugs, dramatically improves market access and affordability. This follows Eli Lilly's outstanding Q1 2026 financial results, which saw revenue increase by 56% driven by strong obesity drug sales, as reported in the 8-K and 10-Q on April 30th. Expanded coverage by a major pharmacy benefit manager is critical for driving sales growth of Eli Lilly's blockbuster obesity franchise. The impact of these coverage changes on sales volumes will become clearer in Q3 and Q4 results.
At the time of this announcement, LLY was trading at $1,128.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.